| Field | Specification |
|---|---|
| Target | |
| Alternative names | 4′‐BR |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C14H11BrO2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
4'-Bromo-resveratrol, also known as 4′-BR, is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. It induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhibits proliferation; it also reduces lactate production, glucose uptake, and the NAD+/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). It can be used in melanoma research[1]. It is supplied as a white to off-white solid (C14H11BrO2, MW 291.14) at 99.94% purity.
Physical & Chemical Properties
| CAS Number | 1224713-90-9 |
|---|---|
| Molecular Formula | C14H11BrO2 |
| Molecular Weight | 291.14 g/mol |
| Purity | 99.94% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | OC1=CC(O)=CC(/C=C/C2=CC=C(C=C2)Br)=C1 |
| Target | SIRT1, SIRT3, Caspase 3, Caspase 8, GLUT1, LDHA |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics; Apoptosis; Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel |
| Solubility | In Vitro: DMSO: 250 mg/mL (858.69 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, protect from light. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
SIRT1 0.2 mM (IC50) |
SIRT3 0.2 mM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 250 mg/mL (858.69 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
Proliferation and viability of G361, SK-MEL-28, and SK-MEL-2 human melanoma cells are inhibited by 4'-Bromo-resveratrol (0.0125-0.2 mM; 24-72 h) in a dose- and time-dependent manner[1]. In G361, SK-MEL-28, and SK-MEL-2 human melanoma cells, 4'-Bromo-resveratrol (0.0125-0.2 mM; 48 h) impairs clonogenic survival dose-dependently[1]. 4'-Bromo-resveratrol (0.0125-0.05 mM; 24-72 h) induces apoptosis in G361, SK-MEL-28, and SK-MEL-2 human melanoma cells in a dose- and time-dependent manner, with apoptotic morphological changes that include nuclear condensation and fragmentation[1]. After 48 hours of treatment, 4'-Bromo-resveratrol (0.05 mM; 48 h) mediates G0/G1 phase arrest via P21-induced inhibition of Cyclin D1 and CDK6 in G361, SK-MEL-28, and SK-MEL-2 human melanoma cells[1]. In G361, SK-MEL-28, and SK-MEL-2 human melanoma cells, 4'-Bromo-resveratrol (0.05 mM; 48 h) lowers expression of the glycolysis-related proteins LDHA and GLUT1 after 48 hours of treatment[1]. Migration of G361, SK-MEL-28, and SK-MEL-2 human melanoma cells is significantly inhibited by 4'-Bromo-resveratrol (0.05 mM; 48 h)[1]. 4'-Bromo-resveratrol (0.025-0.05 mM; 48 h) dose-dependently suppresses aerobic glycolysis in G361, SK-MEL-28, and SK-MEL-2 human melanoma cells, lowering lactate production, glucose uptake, and the NAD+/NADH ratio[1].
Cell Proliferation Assay[1]
| Cell Line | G361, SK-MEL-28, SK-MEL-2 cells |
|---|---|
| Concentration | 0.0125, 0.025, 0.05, 0.1, 0.2 mM |
| Incubation Time | 24 h, 48 h, 72 h |
| Result | Inhibited melanoma cell proliferation and viability in a dose- and time-dependent manner. Caused massive reduction in proliferation at 0.1 mM and 0.2 mM. Induced appreciable growth inhibition at 0.025 mM, with statistically significant differences compared to vehicle control. |
Apoptosis Analysis[1]
| Cell Line | G361, SK-MEL-28, SK-MEL-2 |
|---|---|
| Concentration | 0.0125, 0.025, 0.05 mM |
| Incubation Time | 24 h, 48 h, 72 h |
| Result | Increased the percentage of apoptotic cells across all three melanoma cell lines in a dose- and time-dependent manner. Showed statistically significant differences compared to vehicle control. |
Western Blot Analysis[1]
| Cell Line | G361, SK-MEL-28, SK-MEL-2 |
|---|---|
| Concentration | 0.05 mM |
| Incubation Time | 48 h |
| Result | Decreased protein levels of procaspase-3 and procaspase-8. Increased levels of cleaved caspase-3. Induced cleavage of full-length PARP (116 kDa) to its 89 kDa cleaved product. Significantly diminished expression of PCNA across all three melanoma cell lines.\nAttenuated protein levels of Cyclin D1 and CDK6 across all three melanoma cell lines. Induced expression of the CDK inhibitor P21 across all three melanoma cell lines.\nSignificantly decreased protein levels of lactate dehydrogenase A (LDHA) across all three melanoma cell lines. Reduced expression of glucose transporter 1 (GLUT1) across all three melanoma cell lines. |
Cell Cycle Analysis[1]
| Cell Line | G361, SK-MEL-28, SK-MEL-2 |
|---|---|
| Concentration | 0.05 mM |
| Incubation Time | 48 h |
| Result | Caused a significant increase in the percentage of cells in the G0/G1 phase across all three melanoma cell lines. Induced a concomitant decrease in the G2/M phase population across all three melanoma cell lines. Showed statistically significant differences compared to vehicle control. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
